Nouri review

The full ladder includes a genuine monthly choice

Nouri’s August pricing page lists compounded semaglutide at $175 billed monthly, $435 for three months or $720 for six months. The lowest $120 monthly figure in its marketing is the equivalent attached to the six-month purchase, not an amount a reader can elect to pay monthly without that commitment.

Tirzepatide has a separate ladder: $225 monthly, $597 for three months or $1,050 for six months. Those totals make the tradeoff visible. A lower arithmetic average requires buying a longer term, while the single-month option limits the initial financial obligation. Ask for the current prescribed-dose quote before choosing either drug or committing to several months.

Dose-flat does not mean every payment schedule is identical

Nouri says the price remains the same at any dose within the selected cadence. That is a useful financial feature if confirmed for the actual prescription, but the three- or six-month payment remains a larger purchase. Do not confuse stable dose pricing with a right to stop paying after any given month of a prepaid term.

The program describes nutrition and movement plans plus physician messaging without an additional tier. Ask what those components involve, who provides individualized support and how clinical questions reach the treating professional. A messaging channel and a general plan are different services from scheduled medical appointments, even when they appear within the same advertised bundle.

Both clinical and pharmacy organizations are named

Nouri identifies F&F Pharmacies Inc., doing business as Jungle Jim’s Pharmacy in Fairfield, Ohio, as the compounding pharmacy. Its clinical organization is Wasef Health, PC, associated with Michael Wasef, MD. Those disclosures provide concrete parties to investigate rather than leaving the service entirely behind a consumer brand.

Confirm the actual clinician and pharmacy assigned to the prescription, along with the product’s ingredients, concentration, quantity and storage instructions. A named 503A pharmacy is useful accountability, but it does not make a compounded finished medication FDA-approved or establish equivalence to a named approved brand. The prescriber should explain the actual formulation and treatment choice.

Availability and enrollment are separate checks

Nouri claims service in all fifty states while noting that some require a video visit before prescribing. It does not identify which states have that requirement in its public information. Ask whether a live appointment is required for the intended location, how it is scheduled and whether it is included in the selected plan.

The homepage’s enrollment links led to error pages in the August 21 review. That is a dated usability problem, not proof that Nouri is closed or that the same failure still occurs. Contact the service to confirm a functioning enrollment route and current availability before relying on a program whose price page is easier to evaluate than its earlier signup links.

A long purchase deserves clear interruption terms

Obtain the payment authorization, cancellation deadline and refund conditions before choosing a three- or six-month package. A first-month discount code does not establish a continuing rate or a refund after medication has been prepared. Ask how a changed prescription affects remaining supplies and whether stopping one part of the program ends every related charge.

Nouri’s public material does not describe dedicated pregnancy, breastfeeding or postpartum guidance. It may interest someone who values named care partners and a visible monthly-versus-prepaid ladder, provided current access is confirmed. The decision should use the actual upfront amount, usable clinical contact and applicable agreement, with the $120 headline retained as a six-month equivalent rather than a flexible monthly offer.